The role of caspase III inhibition in methamphetamine-induced alterations in p53 and bcl-2 expression: correlation with dopaminergic neurotoxicity.
Imam
Syed Z
SZ
Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, Arkansas 72079, USA.
Oetinger
Michelle
M
Skinner
JohnT
J
Slikker
W
W
Ali
Syed F
SF
D000818:Animals; D053148:Caspase 3; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
D061945:Caspase Inhibitors; D015259:Dopamine Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D008694:Methamphetamine; C505409:Casp3 protein, mouse; D053148:Caspase 3; D020169:Caspases